Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007201
Chunk: 107

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 107
---
 not know how long the selling shareholders
will hold the warrants, whether any will exercise the warrants, and upon such exercise, how long such selling shareholders will hold the
Ordinary Shares represented by Depositary Shares before selling them, and we currently have no agreements, arrangements or understandings
with the selling shareholders regarding the sale of any of the shares.

The table below lists the selling shareholders
and other information regarding the beneficial ownership of the Ordinary Shares represented by Depositary Shares by each of the selling
shareholders. The second column lists the number of Ordinary Shares represented by Depositary Shares beneficially owned by each selling
shareholder, based on its ownership of Depositary Shares and warrants to purchase Depositary Shares, as of April 1, 2025 assuming exercise
of the warrants held by the selling shareholders on that date, without regard to any limitations on conversions or exercises. The third
column lists the maximum number of Ordinary Shares represented by Depositary Shares being offered in this prospectus by the selling shareholders.
The fourth and fifth columns list the amount of Ordinary Shares represented by Depositary Shares owned after the offering, by number of
Ordinary Shares represented by Depositary Shares and percentage of outstanding Ordinary Shares, assuming in both cases the sale of all
of the Ordinary Shares represented by Depositary Shares offered by the selling shareholders pursuant to this prospectus, and without regard
to any limitations on conversions or exercises.

In accordance with the terms of a registration
rights agreement with the selling shareholders, this prospectus generally covers the resale of the sum of (i) the number of Ordinary Shares
issued to the selling shareholders at the Closing and the number of Ordinary Shares issued to the selling shareholders upon the exercise
of the warrants issued at the Closing and (ii) the maximum number of Ordinary Shares upon exercise of the related warrants, determined
as if the outstanding warrants were exercised in full as of the trading day immediately preceding the date this registration statement
was initially filed with the SEC, each as of the trading day immediately preceding the applicable date of determination and all subject
to adjustment as provided in the registration right agreement, without regard to any limitations on the exercise of the warrants.

Under the terms of the warrants, a selling
shareholder may not exercise the warrants to the extent such exercise would cause such selling shareholder, together with its affiliates
and attribution parties, to beneficially own a number of Ordinary Shares which would exceed 4.99% or 9.99%, as applicable, of our then
outstanding Ordinary Shares following such